These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 18454043)

  • 1. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
    Rankin AM; Faller DV; Spanjaard RA
    Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
    Herbert BS; Pongracz K; Shay JW; Gryaznov SM
    Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents.
    Gryaznov SM
    Chem Biodivers; 2010 Mar; 7(3):477-93. PubMed ID: 20232321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of telomerase inhibitors.
    Kleideiter E; Piotrowska K; Klotz U
    Methods Mol Biol; 2007; 405():167-80. PubMed ID: 18369824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide N3' --> P5' thio-phosphoramidate telomerase template antagonists as potential anticancer agents.
    Gryaznov S; Asai A; Oshima Y; Yamamoto Y; Pongracz K; Pruzan R; Wunder E; Piatyszek M; Li S; Chin A; Harley C; Akinaga S; Yamashita Y
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):577-81. PubMed ID: 14565232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease.
    Tárkányi I; Aradi J
    Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to inhibit telomerase activity for cancer therapy.
    Kyo S; Inoue M
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):613-26. PubMed ID: 12678728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anticancer therapeutics targeting telomerase.
    Ruden M; Puri N
    Cancer Treat Rev; 2013 Aug; 39(5):444-56. PubMed ID: 22841437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Telomeres and telomerase as targeted therapies in cancer treatment].
    Souiden Y; Bouraoui A; Chaieb K; Mahdouani K
    Bull Cancer; 2010 Sep; 97(9):1087-104. PubMed ID: 20663741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomere maintenance mechanisms as a target for drug development.
    Bearss DJ; Hurley LH; Von Hoff DD
    Oncogene; 2000 Dec; 19(56):6632-41. PubMed ID: 11426649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting human telomerase in cancer therapy.
    Huard S; Autexier C
    Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):577-87. PubMed ID: 12678725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors.
    Mueller S; Hartmann U; Mayer F; Balabanov S; Hartmann JT; Brummendorf TH; Bokemeyer C
    Invest New Drugs; 2007 Dec; 25(6):519-24. PubMed ID: 17534576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.
    Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM
    Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting telomerase and telomeres to enhance ionizing radiation effects in in vitro and in vivo cancer models.
    Berardinelli F; Coluzzi E; Sgura A; Antoccia A
    Mutat Res Rev Mutat Res; 2017 Jul; 773():204-219. PubMed ID: 28927529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomerase inhibition and telomere targeting in hematopoietic cancer cell lines with small non-nucleosidic synthetic compounds (BIBR1532).
    El Daly H; Martens UM
    Methods Mol Biol; 2007; 405():47-60. PubMed ID: 18369817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase: a potential therapeutic target for cancer.
    Fletcher TM
    Expert Opin Ther Targets; 2005 Jun; 9(3):457-69. PubMed ID: 15948667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer therapy targeting telomeres and telomerase : current status.
    Parkinson EK; Minty F
    BioDrugs; 2007; 21(6):375-85. PubMed ID: 18020621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells.
    Zhou G; Liu X; Li Y; Xu S; Ma C; Wu X; Cheng Y; Yu Z; Zhao G; Chen Y
    Oncotarget; 2016 Mar; 7(12):14925-39. PubMed ID: 26908447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomeres, telomerase and cancer: is the magic bullet real?
    Sharma HW; Maltese JY; Zhu X; Kaiser HE; Narayanan R
    Anticancer Res; 1996; 16(1):511-5. PubMed ID: 8615664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.